JP2006509830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509830A5 JP2006509830A5 JP2004563716A JP2004563716A JP2006509830A5 JP 2006509830 A5 JP2006509830 A5 JP 2006509830A5 JP 2004563716 A JP2004563716 A JP 2004563716A JP 2004563716 A JP2004563716 A JP 2004563716A JP 2006509830 A5 JP2006509830 A5 JP 2006509830A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- dendritic
- use according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/320,779 US20040115224A1 (en) | 2002-12-16 | 2002-12-16 | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
| PCT/US2003/040284 WO2004057968A1 (en) | 2002-12-16 | 2003-12-16 | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509830A JP2006509830A (ja) | 2006-03-23 |
| JP2006509830A5 true JP2006509830A5 (https=) | 2007-02-08 |
Family
ID=32506941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563716A Pending JP2006509830A (ja) | 2002-12-16 | 2003-12-16 | 癌予防用ハイブリッド細胞ワクチンの調製および投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040115224A1 (https=) |
| EP (1) | EP1583424A4 (https=) |
| JP (1) | JP2006509830A (https=) |
| AU (1) | AU2003301023A1 (https=) |
| CA (1) | CA2508209A1 (https=) |
| IL (1) | IL169124A0 (https=) |
| WO (1) | WO2004057968A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002225990B2 (en) * | 2000-10-20 | 2007-07-19 | Tsuneya Ohno | Fusion cells and cytokine compositions for treatment of disease |
| US20050180951A1 (en) * | 2004-02-12 | 2005-08-18 | Tsuneya Ohno | Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
| AU2005218638A1 (en) * | 2004-03-02 | 2005-09-15 | Donald W. Kufe | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer |
| WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| JP5721428B2 (ja) * | 2007-04-27 | 2015-05-20 | バヴァリアン・ノルディック・アクティーゼルスカブ | マクロファージ−コロニー刺激因子（ｍ−ｃｓｆ）による樹状細胞発生の誘導 |
| US9695397B2 (en) | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| JP2022542745A (ja) * | 2019-05-27 | 2022-10-07 | 錦高キャピタル株式会社 | 樹状細胞ベースの癌ワクチン及びその調製方法 |
| WO2022108306A1 (ko) * | 2020-11-17 | 2022-05-27 | 성균관대학교산학협력단 | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3519404A1 (de) * | 1984-06-07 | 1985-12-12 | Marginvest S.A. Holding, Luxemburg/Luxembourg | Verfahren zur herstellung eines absorptions- und adsorptionsmittels, sowie nach diesem verfahren hergestelltes absorptions- und adsorptionsmittel |
| US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| ATE388237T1 (de) * | 1997-04-15 | 2008-03-15 | Dana Farber Cancer Inst Inc | Dendritische zellhybride |
| US20020041868A1 (en) * | 1997-04-15 | 2002-04-11 | Charles Nicolette | Cell fusions and methods of making and using the same |
| AU3823601A (en) * | 2000-02-11 | 2001-08-20 | Dana Farber Cancer Inst Inc | Cytotoxic t lymphocytes activated by dendritic cell hybrids |
| AU2002225990B2 (en) * | 2000-10-20 | 2007-07-19 | Tsuneya Ohno | Fusion cells and cytokine compositions for treatment of disease |
-
2002
- 2002-12-16 US US10/320,779 patent/US20040115224A1/en not_active Abandoned
-
2003
- 2003-12-16 WO PCT/US2003/040284 patent/WO2004057968A1/en not_active Ceased
- 2003-12-16 CA CA002508209A patent/CA2508209A1/en not_active Abandoned
- 2003-12-16 EP EP03814133A patent/EP1583424A4/en not_active Withdrawn
- 2003-12-16 AU AU2003301023A patent/AU2003301023A1/en not_active Abandoned
- 2003-12-16 JP JP2004563716A patent/JP2006509830A/ja active Pending
-
2005
- 2005-06-09 IL IL169124A patent/IL169124A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ganguly et al. | Canine transmissible venereal tumour: a review | |
| Pu et al. | Ultrasound-triggered and glycosylation inhibition-enhanced tumor piezocatalytic immunotherapy | |
| Mason et al. | Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy | |
| Bencherif et al. | Injectable cryogel-based whole-cell cancer vaccines | |
| Mattarollo et al. | Transient Foxp3+ regulatory T‐cell depletion enhances therapeutic anticancer vaccination targeting the immune‐stimulatory properties of NKT cells | |
| US7445794B1 (en) | Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors | |
| JP2006509830A5 (https=) | ||
| KR20240068768A (ko) | 환자-유래 이종이식을 가지는 hla-비매칭의 인간화된 nsg 마우스 모델 | |
| US11254941B2 (en) | RNA nanostructures and methods of making and using RNA nanostructures | |
| Zhu et al. | Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors | |
| CN109073637A (zh) | 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法 | |
| US20260083106A1 (en) | Humanized immunodeficient mouse models | |
| Herbert et al. | Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial | |
| CN102753188A (zh) | 治疗脑瘤的方法 | |
| Lu et al. | Design of Light‐Activated Nanoplatform through boosting “eat me” signals for improved CD47‐blocking immunotherapy | |
| Tian et al. | Programing immunogenic cell death in breast tumors with designer DNA frameworks | |
| JP2009541333A (ja) | 修飾リボヌクレアーゼ | |
| KR20160089356A (ko) | 자가 종양 백신 및 방법 | |
| Prasit et al. | Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect | |
| Jensen et al. | An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses | |
| JP2010540681A (ja) | リボヌクレアーゼに基づく治療のための組成物及び方法 | |
| Den Otter et al. | Treatment of transmissible venereal tumors in dogs with intratumoral interleukin-2 (IL-2). A pilot study | |
| Chen et al. | Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics | |
| TW202304486A (zh) | 福涅拉氏菌屬細胞外囊泡製劑 | |
| Miller et al. | Targeted TLR9 agonist elicits effective antitumor immunity against spontaneously arising breast tumors |